Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir for moderate COVID-19
IRCT20200328046886N3Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Dolutegravir + standard treatment with Placebo + standard treatment (2 arms). Primary endpoints: Clinical recovery after 14 days from the start of treatment, No need for intensive care and 4 more. Started Aug 2021; status: completed.
02
Drugs
dolutegravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200328046886N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200328046886N3.